Skip to main content

Clinuvel Pharmaceuticals Value Stock - Dividend - Research Selection

Clinuvel pharmaceuticals

ISIN: AU000000CUV3 , WKN: A0JEGY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Clinuvel Pharmaceuticals Ltd (CLVLF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth ...

2025-04-21
Clinuvel Pharmaceuticals Ltd (CLVLF) reports robust financial performance with a 21% revenue increase, while navigating operational challenges and strategic shifts.

High Growth Tech Stocks To Watch In April 2025

2025-04-14
The Australian market showed strength on Monday, with the IT sector leading gains by 2.6%, buoyed by positive momentum from Wall Street and a rise in materials driven by higher iron ore and gold prices. In this environment, identifying high growth tech stocks involves looking for companies that are capitalizing on current market trends and demonstrating resilience during earnings season, as they can potentially offer significant opportunities for investors seeking exposure to innovative sectors.

ASX Growth Stocks With High Insider Ownership To Watch

2025-03-30
As the Australian market opens nearly flat amid the kickoff of the 2025 election campaign, investors are closely monitoring potential economic impacts and policy shifts that may arise in the coming weeks. In such a climate, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business and may offer resilience during uncertain times.

High Growth Tech Stocks In Australia For March 2025

2025-03-16
As the Australian market navigates a turbulent period marked by global trade tensions and fluctuating indices, investors are keeping a keen eye on high-growth tech stocks that have the potential to thrive amid economic uncertainties. In this environment, identifying promising tech companies involves looking for those with innovative solutions and strong adaptability to shifting market dynamics, making them well-positioned to capitalize on emerging opportunities.

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

2025-03-04
MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, with an immersive exhibition that illuminates the past, present and future of photomedicine. The 4,800-square-foot Pavilion of Photomedicine has been custom built for CLINUVEL for the AAD Meeting to provide an immersive experience on the history, evolution, and future of photomedicine, including CLIN

Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call Transcript

2025-02-28
Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q2 2025 Results Conference Call February 27, 2025 2:00 AM ETCompany ParticipantsStella Mariss - Monsoon...

3 ASX Growth Stocks With Strong Insider Ownership

2025-02-25
As the ASX 200 hits a new 20-day low, driven by global trade tensions and sector-wide declines, investors are navigating a challenging landscape with particular focus on sectors like Utilities and Health Care that have shown resilience. In such fluctuating market conditions, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those closest to the business.

Exploring 3 High Growth Tech Stocks In Australia

2025-02-13
The Australian market is experiencing a slight uptick, with ASX 200 futures indicating a modest gain, diverging from recent U.S. market hesitations due to consumer price concerns and ongoing reporting season dynamics. In this context of cautious optimism and sector-specific developments, identifying high growth tech stocks involves evaluating companies that demonstrate resilience and adaptability amidst fluctuating economic indicators and evolving investor sentiments.